Back to Search
Start Over
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease
- Source :
- The Pharmacogenomics Journal. 19:547-555
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- The production of antibodies to anti-tumor necrosis factor alpha (TNF) agents is one of the main causes of treatment failure in Crohn’s disease (CD). To date, however, the contribution of genetics to anti-TNF immunogenicity in CD is still unknown. The objective of the present study was to identify genetic variation associated with anti-TNF immunogenicity in CD. We performed a two-stage genome-wide association study in a cohort of 96 and 123 adalimumab-treated patients, respectively. In the discovery stage, we identified a genome-wide significant association between the CD96 locus and the production of antibodies to anti-TNF treatment (P = 1.88e–09). This association was validated in the replication stage (P
- Subjects :
- 0301 basic medicine
Pharmacology
Crohn's disease
CD96
biology
business.industry
Immunogenicity
Locus (genetics)
Disease
medicine.disease
030226 pharmacology & pharmacy
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Immunology
Genetics
biology.protein
Molecular Medicine
Medicine
Tumor necrosis factor alpha
Antibody
business
Genetic association
Subjects
Details
- ISSN :
- 14731150 and 1470269X
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- The Pharmacogenomics Journal
- Accession number :
- edsair.doi...........14eb8c3578d10af66e595788eb19c56a